If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston Bi ...

Core Viewpoint - BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics for $4.8 billion, enhancing its portfolio with therapies for lysosomal storage disorders [1] Group 1: Acquisition Details - BioMarin will pay $14.50 per share for Amicus, representing a 33% premium over Amicus' stock value of $10.89 on December 18 [1] - This acquisition is the largest in BioMarin's history and has resulted in a 17.71% increase in BioMarin's stock price, from $51.95 to $61.15 [2] Group 2: Acquired Therapies - The acquisition includes rights to Amicus' Fabry disease therapy, Galafold, which generated $458.1 million in 2024, an 18% increase from 2023 [2] - Galafold is the only FDA-approved chaperone therapy for Fabry disease and has market exclusivity until January 30, 2027, following a patent litigation with Teva Pharmaceuticals [3] - BioMarin will also acquire the FDA-approved Pompe disease combination therapy, Pombiliti plus Opfolda, which generated $22 million in 2024 [4][5] Group 3: Future Growth Strategy - BioMarin has been focusing on growth in the pharmaceutical sector, undergoing significant restructuring in 2024, which included laying off 225 employees [7] - The company has adopted a strong dealmaking strategy, signing 10 deals in 2025, the highest number since 2010 according to GlobalData's Pharmaceutical Intelligence Center [7] - BioMarin is also acquiring rights to the investigational oral small molecule DMX-200, currently in Phase III trials for focal segmental glomerulosclerosis [6]

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy and commercial prospects of its lead product candidate, nimacimab [1][3]. Company Overview - Skye Bioscience, Inc. is a San Diego-based biotech company focused on developing therapies for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities between November 4, 2024, and October 3, 2025, with a deadline for potential lead plaintiff representatives set for January 16, 2026 [1][2]. - The complaint alleges that the company overstated the efficacy of nimacimab and exaggerated its clinical success likelihood [3]. Financial Impact - Following the release of topline results from the 26-week Phase 2a CBeyond study, which indicated that nimacimab did not meet its primary weight-loss endpoint compared to placebo, Skye's share price plummeted by 60%, falling from $4.75 to $1.90 per share [4].

Industry Overview - The drug and biotech sector regained momentum in the latter part of 2025 after a weak first half, setting the stage for a strong year for select stocks [1] - Improved policy clarity following drug pricing agreements with the Trump administration reduced uncertainty, while a rebound in mergers and acquisitions revived investor appetite for risk [1] - Innovation accelerated across high-growth areas such as obesity, gene therapy, inflammation, and neuroscience, with the FDA approving 43 novel therapies as of December 22, 2025 [2] Company Highlights Ionis Pharmaceuticals - Ionis Pharmaceuticals' shares surged 127.6% in 2025, significantly outperforming the industry growth of 5% [5][6] - The company advanced its wholly-owned portfolio, highlighted by the FDA approval of Tryngolza for familial chylomicronemia syndrome, generating $57.4 million in sales in the first nine months of 2025 [9] - Ionis is evaluating Tryngolza in late-stage studies for severe hypertriglyceridemia, with plans to file for FDA label expansion soon [10] - The FDA approved Ionis' second drug, Dawnzera, for hereditary angioedema, with a regulatory filing in the EU expected in early 2026 [11] Structure Therapeutics - Structure Therapeutics' shares surged 127.2% in the past year, compared to the industry's 15.6% growth [13] - The stock rally was driven by positive data from the ACCESS clinical program for aleniglipron, showing up to 15.3% placebo-adjusted weight loss [15][16] - The company plans to initiate phase III development for aleniglipron in mid-2026 and is also developing other candidates for obesity treatment [18] Monopar Therapeutics - Monopar Therapeutics' shares rallied 185.9% in the past year, significantly outperforming the industry [20] - The stock price increase was fueled by positive expectations regarding its lead candidate ALXN-1840 for Wilson disease, following a licensing agreement with AstraZeneca [22] - Monopar plans to submit a regulatory filing with the FDA in early 2026 based on favorable long-term data for ALXN-1840 [26] Kodiak Sciences - Kodiak Sciences' shares rallied 181.1% in the past year, contrasting with the industry's 15.7% decline [27] - The stock's performance reflects growing investor confidence in its late-stage pipeline assets, particularly tarcocimab and KSI-501 [29] - Kodiak plans to submit a regulatory filing for tarcocimab for multiple indications, with top-line data from pivotal studies expected in 2026 [31][33]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. Frontera Therapeutics (Incorporated in the Cayman Islands with limited liability) WARNING The publication of this announcement is required by The ...

Market Overview - US stock futures are showing positive movement as investors anticipate a potential Santa Claus rally during the last trading days of the year [1][3] - Gold and silver are experiencing significant price increases, with gold on track for its strongest annual performance since 1979, rising over 60% [2][18] Cryptocurrency Insights - Bitcoin has faced volatility, with prices dropping from a peak of $126,000 in October, leading to concerns about its annual performance potentially ending in decline for the first time since 2022 [4][7] - Analysts predict a challenging first half of the year for Bitcoin, with price targets ranging from $60,000 to $65,000, followed by a potential rally towards $115,000 by year-end [9][20] - The cryptocurrency market is currently in a "crypto winter," raising questions about the sustainability of its four-year cycle [8][10] Institutional and Regulatory Developments - There are discussions regarding the potential removal of MicroStrategy from major indices like the S&P 500, which could have significant implications for institutional investment in Bitcoin [12][13] - The cryptocurrency ecosystem is under scrutiny, with concerns about the impact of regulatory changes on digital asset treasury companies [15][16] Company News - Warner Brothers Discovery and Paramount Skyance are engaged in a takeover battle, with Paramount increasing its termination fee to $5.8 billion while maintaining the offer price at $30 per share [30][31] - Nvidia is preparing to ship its H200 chips to China, although regulatory approvals are still pending [31] - Clearwater Analytics is going private in a deal valued at $8.7 billion, with shareholders set to receive a 47% premium on their shares [33] Sector Outlook for 2026 - Analysts are focusing on hard assets, including metals and agricultural sectors, as potential investment opportunities for 2026 [36] - The healthcare sector is expected to remain resilient, with companies that facilitate essential services likely to perform well despite broader economic uncertainties [41][52] - There is optimism around biotechnology and semiconductors, with specific companies like TransMedics and contract research organizations being highlighted for their growth potential [43][44]

Core Viewpoint - Niagen Bioscience, Inc. has acquired a comprehensive portfolio of patents related to nicotinamide riboside (NR) from Queen's University Belfast, enhancing its leadership in NAD+ precursor intellectual property [1] Group 1: Company Developments - The acquisition strengthens Niagen's long-standing ownership position in the NAD+ precursor market [1] - The focus of the company is on the science of healthy aging, positioning it as a global authority in NAD+ [1] Group 2: Industry Implications - The acquisition of these patents may lead to increased innovation and product development in the field of healthy aging and NAD+ research [1] - This move could potentially enhance the competitive landscape within the biotech industry, particularly in the area of aging-related health solutions [1]

Company Overview - Stuffers, founded by Jackson and Quincy Fuller, aims to create unique corporate swag in the form of stuffed animals inspired by company logos and mascots [1][2] - The company is positioned to cater to both large and small businesses, providing a creative alternative to traditional corporate gifts [2] Innovation and Technology - Stuffers utilizes AI technology, including OpenAI's real-time voice API and various image generation models, to transform sketches into product-ready designs [3] - The process allows for rapid prototyping of ideas, showcasing the potential of AI in product development [3] Educational Impact - The initiative is seen as a proof of concept for how children can learn business and creativity fundamentals in an AI-driven world [5] - The stuffed animals serve as a playful educational tool, encouraging entrepreneurial thinking among the younger generation [5] Business Goals - Jackson and Quincy have set a target to acquire 50 customers within their first year of operation [6] - The founders express ambitions for broader marketing efforts, including a commercial and billboard advertising [6]

Group 1 - Clearwater Analytics Holdings, Inc. is being acquired by a consortium of private equity firms led by Permira and Warburg Pincus for approximately $8.4 billion, including debt [1] - Following the acquisition announcement, Clearwater Analytics shares increased by 7.6% to $23.93 in pre-market trading [1] Group 2 - Autozi Internet Technology (Global) Ltd. experienced a significant surge of 60% to $4.00 in pre-market trading after confirming a $90 million initial equity investment [4] - Datavault AI Inc. saw a rise of 34.8% to $1.31 in pre-market trading due to the announcement of two foundational U.S. patents related to blockchain-driven content licensing [4] - Vision Marine Technologies Inc. rose by 30.3% to $0.3270 after closing a public offering [4] - Sidus Space, Inc. increased by 20.7% to $1.40 after a previous jump of 35% [4] - Hycroft Mining Holding Corporation gained 14.2% to $18.77 after a 7% increase on the previous trading day [4] - Creative Media & Community Trust Corporation shares jumped 13.2% to $3.61 after a 7% gain on Friday [4] - ABIVAX Société Anonyme gained 10.2% to $126.64 in pre-market trading [4] Group 3 - Luminar Technologies, Inc. fell sharply by 54.8% to $0.2728 after announcing voluntary Chapter 11 proceedings [4] - Mint Incorporation Limited declined by 14.4% to $0.41 after a significant increase of over 75% on Friday [4] - Culp, Inc. reported mixed second-quarter financial results, leading to a 10.1% drop to $3.11 in pre-market trading [4] - Rising Dragon Acquisition Corp. declined by 9.5% to $9.42 following a trust amendment announcement [4] - Hyperscale Data, Inc. fell by 9.2% to $0.2335 after announcing an "at-the-market" offering of common stock [4]

Core Viewpoint - The article discusses the potential for significant growth in tech stocks, particularly in the AI sector, by 2026, with a focus on the monetization of AI technologies and the emergence of new software applications [1][2]. Group 1: Market Outlook - Analysts predict that tech stocks could rise over 20% in 2026, with large-cap stocks, specifically the "Mag Seven," expected to increase by more than 20% [2]. - Companies like Microsoft and Google are anticipated to see stock increases of 30% to 40% [2]. - An estimated $3 trillion to $4 trillion will be spent in the next 3 to 4 years, marking the beginning of a new phase in the AI trade [2]. Group 2: Stock Selection Methodology - The list of "10 Stocks That Will Go To The Moon in 2026" was curated using the Finviz stock screener, CNN, and Insider Monkey's Q3 2025 hedge fund database, focusing on stocks with more than 50% upside potential [5]. - The stocks were ranked based on the number of hedge fund holders, indicating strong institutional interest [5][6]. Group 3: Company Highlights - **BioNTech SE (NASDAQ:BNTX)**: - Analyst upside potential is 53.64% with 24 hedge fund holders [7]. - The company recently acquired CureVac N.V., enhancing its oncology and infectious disease pipeline [8]. - Interim data from a Phase 2 trial for Pumitamig showed a 72% overall response rate in triple-negative breast cancer patients, supporting advancement to a Phase 3 trial [9][10]. - **IonQ, Inc. (NYSE:IONQ)**: - Analyst upside potential is 50.58% with 30 hedge fund holders [12]. - The company expanded its agreement with QuantumBasel, resulting in a contract valued over $60 million [13]. - IonQ's sales are projected to double from 2023 to 2024, with further doubling expected in 2025, indicating strong growth potential [15].